Chargement en cours...

A promising response to osimertinib in a patient with erlotinib-resistant lung adenocarcinoma with an uncommon EGFR mutation

Most patients with non-small cell lung cancer with common epidermal growth factor receptor (EGFR) mutations respond dramatically to EGFR tyrosine kinase inhibitors (TKIs), but data are limited on the response of tumours with uncommon mutations. We present the case of a 68-year-old man with stage IV...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMJ Case Rep
Auteurs principaux: Niwa, Hideyuki, Nakahara, Yoshiro, Sasaki, Jiichiro, Masuda, Noriyuki
Format: Artigo
Langue:Inglês
Publié: BMJ Case Reports 2018
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5990104/
https://ncbi.nlm.nih.gov/pubmed/29866661
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-219770
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!